Gemcitabine in advanced pancreatic cancer: A phase II trial

Crinò, Lucio; Mosconi, A.M.; Calandri, Cesare; Corgna, E.; Darwish, Sara; Tonato, Maurizio

doi:10.1016/s0959-8049(97)86176-x

Cited by 10 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among the many chemotherapeutic agents that have been tested individually or in combination with other agents, gemcitabine, which is a pyrimidine antimetabolite agent, has shown some clinical benefit in unresectable pancreatic cancers, but the response rates are variable and low-often less than 20%. [4][5][6][7] Hypoxia, or a reduction in the normal level of tissue oxygen tension, plays an important role in tumorigenesis, which is noteworthy given the aforementioned hypovascularity of pancreatic tumors. Although hypoxia is toxic to cancer cells, adaptation to hypoxic conditions is often observed within tumors.…”

Section: Introductionmentioning

confidence: 99%

Upregulation of BNIP3 by 5-aza-2′-deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death

et al. 2005

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Upregulation of BNIP3 by 5-aza-2′-deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death

et al. 2005

View full text Add to dashboard Cite

show abstract

“…An OR rate of 16.6% was reported when GEM was administered initially at a dose of 1000 mg/m 2 once each week for 7 consecutive weeks and thereafter for 3 weeks out of every 4 weeks. 21 In all of these Phase II trials, some patients experienced a significant improvement in disease-related symptoms.…”

mentioning

confidence: 99%

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma

Colucci

Giuliani²,

Gebbia

et al. 2002

Cancer

313

145

View full text Add to dashboard Cite

The addition of CDDP to GEM significantly improved the median time to disease progression and the overall response rate compared with GEM alone. The clinical benefit rate was similar in both arms, whereas the median overall survival rate was more favorable for Arm B, although the difference did not attain statistical significance. The authors conclude that the combination of CDDP and GEM currently may be considered as an optimal treatment for patients with locally advanced and/or metastatic adenocarcinoma of the pancreas.

show abstract

“…In spite of these poor results, 2 randomized trials demonstrated that chemotherapy for patients with advanced pancreatic carcinoma improves clinical symptoms and OS by 4 months compared with supportive care [17,18] . Still, life expectancy for the majority of these patients is short, with a median survival between 4 and 10 months [2,19,20] .…”

Section: Discussionmentioning

confidence: 99%

Fixed Dose Rate Infusion of Gemcitabine with Oral Doxifluridine and Leucovorin for Advanced Unresectable Pancreatic Cancer: A Phase II Study

Kim

Park²,

Shin³

et al. 2007

Chemotherapy

View full text Add to dashboard Cite

The standard beneficial chemotherapy proven for patients with advanced pancreatic cancer is a regimen containing gemcitabine. In the pregemcitabine era, 5-fluorouracil (5-FU) was the standard agent. Oral 5-FU can be added to gemcitabine to improve the efficacy of chemotherapy and to provide better patient convenience. The possibility to improve efficacy of gemcitabine by fixed dose rate infusion (FDRI) was proposed in addition to combining it with 5-FU. We tried a new chemotherapy combining FDRI of gemcitabine with doxifluridine and leucovorin. Eligibility criteria were pathologically proven, chemotherapy-naïve, and metastatic or nonoperable advanced pancreatic cancer. Gemcitabine 1,000 mg/m² was infused over 100 min (days 1, 8 and 15). Doxifluridine 200 mg/m² t.i.d. and leucovorin 15 mg b.i.d. were given orally (days 1–21). Chemotherapy was repeated every 28 days until a patient had received 6 cycles or progression was found. Twenty-nine patients were enrolled from October 2002 to December 2004. A total of 78 cycles were given at a mean of 2.7 cycles per patient. Response could be evaluated in 26 patients. Responses were partial remission in 4/26 patients (15.4%), stable disease in 8/26 (30.8%) and progression in 14/26 (53.8%). All patients progressed except for 2 in partial remission and 2 in stable disease. Toxicities could be assessed in 23 patients. Maximal hematological toxicities greater than grade 2 were leucopenia in 3 patients (11.5%), neutropenia in 2 (7.7%), anemia in 2 (7.7%), thrombocytopenia in 1 (3.8%) and febrile neutropenia in 3 (11.5%). Maximal nonhematological grade 3 or 4 toxicities were asthenia in 1 patient (3.8%), anorexia in 1 (3.8%), vomiting in 1 (3.8%), diarrhea in 2 (7.7%), allergic reaction in 1 (3.8%), hand-foot syndrome in 1 (3.8%) and hyperbilirubinemia in 1 (3.8%). All 29 patients were dead on last follow-up. Median progression-free survival was 3.91 months in 26 evaluable patients and median overall survival was 5.59 months in all patients. Combination chemotherapy including FDRI of gemcitabine seems minimally active for patients with advanced, nonoperable pancreatic cancer. Further research to improve effectiveness of chemotherapy for advanced pancreatic cancer is mandatory.

show abstract

Gemcitabine in advanced pancreatic cancer: A phase II trial

Cited by 10 publications

References 0 publications

Upregulation of BNIP3 by 5-aza-2′-deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death

Upregulation of BNIP3 by 5-aza-2′-deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma

Fixed Dose Rate Infusion of Gemcitabine with Oral Doxifluridine and Leucovorin for Advanced Unresectable Pancreatic Cancer: A Phase II Study

Contact Info

Product

Resources

About